期刊文献+

米托蒽醌和多西紫杉醇联合用药对乳腺癌治疗的影响 被引量:2

下载PDF
导出
摘要 目的探讨米托蒽醌与多西紫杉醇联合对人乳腺癌细胞株MCF-7裸鼠皮下移植瘤生长的影响。方法建立人乳腺癌细胞株MCF-7裸鼠皮下移植瘤模型,观察移植瘤生长情况,计算抑瘤率,免疫组化法检测组织中增殖细胞核抗原(PCNA)和Ki67的表达,Western blot检测细胞凋亡相关蛋白磷酸酶和张力蛋白同源基因(PTEN)的表达。结果在米托蒽醌与多西紫杉醇共同处理条件下MCF-7细胞成瘤实验的抑瘤率明显上升。用药后,PCNA和Ki67蛋白阳性率降低,PTEN蛋白表达上升。结论米托蒽醌联合多西紫杉醇可能通过改变细胞凋亡相关基因的表达,进而对抑制或逆转乳腺癌的发展起到有一定的作用。
作者 邱芳
出处 《山东医药》 CAS 北大核心 2011年第24期48-49,共2页 Shandong Medical Journal
  • 相关文献

参考文献6

  • 1Heys SD, Sarkar T, Hutcheon AW. Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer [ J]. Expert Opin Pharmacother, 2004,5(10) :2147-2157.
  • 2Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, muhicentre trial [J]. Lancet, 2002,360(9350) :2018-2025.
  • 3Valero V. Primary chemotherapy with docetaxel for the management of breast cancer [ J ]. Ontology, 2002,16 (6 Suppl 6) :35-43.
  • 4Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA) : a dancer with many partners [ J ]. J Cell Sci, 2003,116 ( Pt 15 ) : 3051-3060.
  • 5Urrutieoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer [J]. J Clin Oncol, 2005,23(28) :7212-7220.
  • 6Depowski PL, Rosenthal SI, Ross JS, et al. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer [J]. 2001,14(7) :672-676.

同被引文献32

  • 1张会清,王光辉.吡柔比星膀胱灌注预防浅表膀胱肿瘤复发的临床研究[J].中国医师杂志,2006,8(12):1718-1719. 被引量:3
  • 2英焕春,吕靖,张淑兰.凋亡相关基因及蛋白的表达与人卵巢癌细胞顺铂耐药的关系[J].中国现代医学杂志,2007,17(7):820-824. 被引量:10
  • 3Siegel R, Ward E, Brawley O,et ak The impact of eliminating socioeconomic and racial disparities on premature cancer deaths [J]. CA-A Cancer Journal for Clinicians, 2011,61 (4) : 212-236.
  • 4Chan Y, Ng T, Ngan H,et al. Quality of life in women treated withneoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study [J]. Gynecologic Oncology, 2003,88( 1 ):9-16.
  • 5Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives [J]. Future Oncology, 2010,6(4) :527-537.
  • 6Jnicke RU. MCF-7 breast carcinoma cells do not express caspase-3 [J]. Breast cancer research and treatment, 2009,117 ( 1 ) : 219-221.
  • 7Xu HL, Xu WH, Cai Q, et al. Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population [J]. Cancer Epidemiology Biomarkers & Prevention, 2009,18(7 ) : 2114-2122.
  • 8Babjuk M, Oosterlinck W, Sylvester R, et at. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. Eur Urol, 2011,59(6) :997-1008.
  • 9Malmst~m PU, Sylvester R J, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu6rin for non-muscle-invasive bladder cancer [ J ]. Eur Urol, 2009,56(2) :247-256.
  • 10Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC) : a sys- tematic review[J]. BJU Int, 2012,109(4) :496-505.

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部